Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $59.13 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-03-18
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2017-03-31 was $0.00.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was $59.13, a 325.40% increase from fiscal 2024.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was $13.90, a 51.91% increase from fiscal 2023.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was $9.15, a 41.23% decline from fiscal 2022.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was $15.57.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $59.13 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $13.90 10-K · filed 2025-03-21 | |||
| 2023-12-31 | $9.15 10-K · filed 2024-03-22 | |||
| 2022-12-31 | $15.57 10-K · filed 2023-03-22 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-24 | |||
| 2020-12-31 | $5.34 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $0.89 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.89 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $1.29 10-K · filed 2020-03-19 | |||
| 2019-09-30 | $1.29 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $1.75 10-K · filed 2019-02-21 | |||
| 2018-09-30 | $1.75 10-Q · filed 2018-11-13 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $0.14 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |